WO2013044603A1 - Dispositif médical d'intervention et son procédé de fabrication - Google Patents

Dispositif médical d'intervention et son procédé de fabrication Download PDF

Info

Publication number
WO2013044603A1
WO2013044603A1 PCT/CN2012/070400 CN2012070400W WO2013044603A1 WO 2013044603 A1 WO2013044603 A1 WO 2013044603A1 CN 2012070400 W CN2012070400 W CN 2012070400W WO 2013044603 A1 WO2013044603 A1 WO 2013044603A1
Authority
WO
WIPO (PCT)
Prior art keywords
drug
stent
medical device
stent body
proliferation
Prior art date
Application number
PCT/CN2012/070400
Other languages
English (en)
Chinese (zh)
Inventor
张大东
蔡煦
乐承筠
李俊菲
胡燕
黄鹏
唐智荣
罗七一
Original Assignee
上海微创医疗器械（集团）有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 上海微创医疗器械（集团）有限公司 filed Critical 上海微创医疗器械（集团）有限公司
Priority to EP12834752.3A priority Critical patent/EP2762110A4/fr
Priority to IN2578CHN2014 priority patent/IN2014CN02578A/en
Priority to US14/348,857 priority patent/US20140248327A1/en
Priority to BR112014007580A priority patent/BR112014007580A2/pt
Publication of WO2013044603A1 publication Critical patent/WO2013044603A1/fr
Priority to US14/677,741 priority patent/US9433709B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/08—Materials for coatings
    • A61L31/10—Macromolecular materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/146—Porous materials, e.g. foams or sponges
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/16—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2250/00—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2250/0058—Additional features; Implant or prostheses properties not otherwise provided for
    • A61F2250/0067—Means for introducing or releasing pharmaceutical products into the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2250/00—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2250/0058—Additional features; Implant or prostheses properties not otherwise provided for
    • A61F2250/0067—Means for introducing or releasing pharmaceutical products into the body
    • A61F2250/0068—Means for introducing or releasing pharmaceutical products into the body the pharmaceutical product being in a reservoir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/416—Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2420/00—Materials or methods for coatings medical devices
    • A61L2420/02—Methods for coating medical devices

Definitions

  • the present application relates to the field of medical device technology, and in particular to an interventional medical device containing a drug and a preparation method thereof.
  • Background technique
  • a drug-coated coating is applied to the stent implanted in the human body.
  • Most of the drug stents currently used are drugs that inhibit the intimal or mesenteric proliferation, such as: rapamycin, paclitaxel, and derivatives thereof.
  • the stent carrying the above drugs is implanted into the human body, the stent will be Drugs that inhibit the intimal or medial hyperplasia are continuously released to the vessel wall to reduce the incidence of in-stent restenosis.
  • intravascular restenosis is not only related to intimal or mesenteric hyperplasia after vascular injury, but also related to vascular remodeling, and vascular remodeling is the main factor in the formation of in-stent restenosis, which may account for restenosis. Seventy percent of the causes, and endocardial or medial hyperplasia accounted for only 30% of the possible causes of restenosis.
  • existing drug stents that inhibit intimal or medial hyperplasia do not minimize the incidence of in-stent restenosis.
  • existing drugs that inhibit the intimal or mesenteric proliferation such as rapamycin, paclitaxel, and their derivatives, inhibit the growth of endothelial cells, leading to delayed endothelialization, and may not be fully endothelialized. causess late thrombosis.
  • the embodiments of the present application provide an interventional medical device and a preparation method thereof, which can inhibit the proliferation of the outer membrane fibroblasts after being implanted into the human body, promote the compensatory expansion of the blood vessels, and can also inhibit the blood vessels. Intimal hyperplasia to reduce the incidence of in-stent restenosis.
  • An interventional medical device comprising: a stent body, the surface of the stent body is provided with a drug
  • the release structure, the drug in the drug release structure is a drug that inhibits proliferation of outer membrane fibroblasts and a drug that inhibits proliferation of endometrial and/or smooth muscle cells.
  • the drug releasing structure is a dense mixed layer of a high molecular polymer and a drug which inhibits proliferation of outer membrane fibroblasts and a drug which inhibits proliferation of endometrial and/or smooth muscle cells.
  • the high molecular polymer comprises: polylactic acid, polyethylene glycol, styrene butene copolymer, polycaprolactone, polybutyl methacrylate, polyethyl methacrylate, ethyl acetate ethyl acetate , polyurethane, polyvinylpyrrolidone, poly-tartrate, silk fibroin, gelatin, chitin and/or hyaluronic acid.
  • the drug release structure is a microporous coating structure formed on the surface of the stent body or formed on the surface of the stent body, and is contained in the microporous structure or the microporous coating structure. Into the drug.
  • the drug for inhibiting proliferation of outer membrane fibroblasts comprises at least one of tanshinone, asiaticoside, centella asiatica, ligustrazine, scutellarin, sulvastatin, and angiotensin.
  • the drug for inhibiting proliferation of endometrial and/or smooth muscle cells comprises: at least one of rapamycin and a derivative thereof, paclitaxel and a derivative thereof.
  • the stent body comprises: a coronary artery stent, an intracranial vascular stent, a peripheral vascular stent, an intraoperative stent, a heart valve stent, a biliary stent, an esophageal stent, an intestinal stent, a pancreatic duct stent, a urethral stent or a tracheal stent. .
  • a method of preparing an interventional medical device comprising:
  • the interventional medical device is obtained by drying the stent body.
  • the microporous structure is prepared on the surface of the stent body, specifically:
  • Micropores are formed on the surface of the stent body by anodization, micro-arc oxidation, and/or chemical etching.
  • the microporous structure is prepared on the surface of the stent body, specifically:
  • a coating having micropores is prepared on the surface of the stent body.
  • the drug in the formulated solution is loaded into the microporous structure, specifically: loading the drug in the solution by ultrasonic spraying, air spraying and/or dip coating In the micropore structure.
  • a method of preparing an interventional medical device comprising:
  • a mixed solution of a drug and a high molecular polymer for inhibiting proliferation of outer membrane fibroblasts a mixed solution of a drug and a high molecular polymer for inhibiting proliferation of endometrial and/or smooth muscle cells, or a membrane inhibiting proliferation of outer membrane fibroblasts a drug and a mixed solution of a drug and a high molecular polymer that inhibits proliferation of endometrial and/or smooth muscle cells;
  • a mixed solution of a drug and a high molecular polymer which inhibits proliferation of outer membrane fibroblasts, and a mixed solution of a drug and a high molecular polymer which inhibit proliferation of endometrial and/or smooth muscle cells are sequentially coated on the surface of the stent body, or may be inhibited a drug for proliferating outer membrane fibroblasts and a mixed solution of a drug and a high molecular polymer for inhibiting proliferation of endometrial and/or smooth muscle cells are coated on the surface of the stent body;
  • the interventional medical device is obtained by drying the stent body.
  • the coating comprises: ultrasonic spraying, air spraying, and/or dip coating.
  • the drug carried on the outer membrane fibroblast proliferation can be slowly released into the blood vessel wall cells in contact with the stent body, and further It can inhibit the proliferation of adventitial fibroblasts, inhibit the proliferation of fibroblasts and play a role in vascular remodeling, which is beneficial to the compensatory expansion of damaged vessels, thereby reducing the incidence of in-stent restenosis;
  • Membrane and/or smooth muscle cell proliferation drugs can also inhibit the intimal hyperplasia to a certain extent, and the two drugs work together to greatly reduce the incidence of in-stent restenosis.
  • the medical device provided by the embodiments of the present application not only has a lower inhibition rate on endothelial cells, but also promotes endothelial cells. Growth, speeding up the process of endothelialization.
  • FIG. 1 is a schematic structural view of a specific embodiment of an interventional medical device provided by the present application
  • 2 is a schematic structural view of another embodiment of the interventional medical device provided by the present application
  • FIG. 3 is a schematic structural view of another embodiment of the interventional medical device provided by the present application
  • FIG. 5 is another process flow of the preparation method of the interventional medical device provided by the present application
  • FIG. 6 is another process flow of the preparation method of the interventional medical device provided by the present application
  • 7 is another process flow of the method for preparing an interventional medical device provided by the present application.
  • An embodiment of the present application provides an interventional medical device, comprising: a stent body, wherein: a drug release structure is disposed on a surface of the stent body, and the drug in the drug release structure is a drug for inhibiting proliferation of outer membrane fibroblasts and inhibiting Membrane and/or smooth muscle cell proliferation drugs.
  • FIG. 1 is a schematic structural view of a specific embodiment of an interventional medical device provided by the present application.
  • 1 is a stent body
  • 2 is a drug # discharge coating
  • a drug release coating 2 is coated on the outer surface of the stent body 1, wherein:
  • the stent body 1 may be a coronary artery stent, an intracranial vascular stent, a peripheral vascular stent, an intraoperative stent, a heart valve stent, a biliary stent, an esophageal stent, an intestinal stent, a pancreatic duct stent, a urethral stent or a tracheal stent, and the stent body
  • the material of 1 may be stainless steel, cobalt-based alloy, nickel-based alloy, titanium alloy, degradable magnesium alloy or polymer material with good biocompatibility and mechanical properties.
  • the drug release coating 2 is a dense mixed layer formed of a high molecular polymer and a drug which inhibits proliferation of outer membrane fibroblasts and a drug which inhibits proliferation of endometrial and/or smooth muscle cells, that is, the drug release coating 2 as a carrier, which can make
  • the surface of the stent body 1 carries a drug.
  • the drug for inhibiting the proliferation of the outer membrane into the sputum cell comprises at least one of tanshinone, asiaticoside, hydroxysalicum, ligustrazine, scutellarin, sulvastatin, angiotensin, in the embodiment of the present application.
  • the drug which inhibits proliferation of endometrial and/or smooth muscle cells may be at least one of rapamycin and its derivatives, paclitaxel and derivatives thereof, preferably rapamycin.
  • the high molecular polymer in the drug release coating 2 may be a high molecular polymer having biocompatibility and controlled release properties, such as polylactic acid, polyethylene glycol, styrene butene copolymer, polycaprolactone.
  • polybutyl methacrylate polyethyl methacrylate, ethyl acetate ethyl acetate, polyurethane, polyvinylpyrrolidone, polycholine, silk fibroin, gelatin, chitin and/or hyaluronic acid.
  • Centella asiatica is a total sputum extracted from Centella asiatica, and it can inhibit the pathogenesis of TGF-
  • asiaticoside also promotes endothelial cell growth and accelerates the endothelialization process.
  • PCI classification number R541.4 article number: 1671-8259 (2005) 05-0477-03.
  • the interventional medical device provided by the embodiment of the present application can promote the growth of endothelial cells and accelerate the progress of endothelialization as compared with the prior art drug stents using rapamycin, paclitaxel and derivatives thereof.
  • FIG. 2 is a schematic structural view of another embodiment of the interventional medical device provided by the present application.
  • 1 is a stent body
  • 3 is a micropore formed on the surface of the stent.
  • the drug releasing structure is a micropore 3 which can be obtained by oxidizing or etching the surface of the stent body 1.
  • the drug can be loaded in the micropores 3, so that the surface of the stent body 1 can carry the drug.
  • FIG. 3 is a schematic structural view of still another embodiment of the interventional medical device provided by the present application.
  • the hole 3 is obtained by directly oxidizing or etching the surface of the stent body 1.
  • a layer can be prepared on the surface of the stent body 1.
  • FIG. 4 is a process flow of a method for preparing an interventional medical device provided by the present application.
  • the stent body is exemplified by a metal stent
  • the preparation method of the interventional medical device includes:
  • Step S101 Cleaning the stent body and drying.
  • Step S102 preparing micropores on the surface of the stent body.
  • Electroporation and/or chemical etching are used to form micropores on the surface of the stent body, wherein electro-chemical corrosion includes anodization, micro-arc oxidation, and the like. Through this step, micropores can be formed on the surface of the stent body, and a schematic structural view thereof is shown in FIG.
  • Step S103 A solution containing a drug that inhibits proliferation of outer membrane fibroblasts and a drug that inhibits proliferation of endometrial and/or smooth muscle cells is prepared.
  • the drug for inhibiting the proliferation of the outer membrane fibroblast is asiaticoside
  • the drug for inhibiting the proliferation of the inner membrane and/or the smooth muscle cell is rapamycin
  • the asiaticoside and the rapa are formulated.
  • 10 mg of rapamycin and 30 mg of asiaticoside can be dissolved in 10 ml of ethanol solution, dissolved and uniformly mixed.
  • Step S104 Loading the drug in the prepared solution into the pore of the stent body.
  • the stent body having the microporous surface obtained in the step S102 is immersed in the solution prepared in the step S103, so that the drug in the solution can be loaded in the micropores on the surface of the stent body.
  • Step S105 drying the stent body to obtain an interventional medical device.
  • FIG. 5 is another process flow of the method for preparing an interventional medical device provided by the present application.
  • the method for preparing the interventional medical device includes: Step S201: The holder body is cleaned and dried.
  • Step S202 preparing a coating having micropores on the surface of the stent body.
  • the specific operation procedure is as follows: the silk fibroin solution is covered on the surface of the stent body, denatured by heat or chemical reagent, and then infiltrated with pure water, then frozen and warmed to dry, and a coating having a microporous structure is formed on the surface of the stent body.
  • Floor the surface of the stent body.
  • Step S203 A solution containing a drug that inhibits proliferation of outer membrane fibroblasts and a drug that inhibits proliferation of endometrial and/or smooth muscle cells is prepared.
  • the drug for inhibiting the proliferation of the outer membrane fibroblast is asiaticoside
  • the drug for inhibiting the proliferation of the inner membrane and/or the smooth muscle cell is rapamycin
  • 10 mg may be used. Rapamycin and 50 mg of asiaticoside were dissolved in 10 ml of ethanol solution, dissolved and mixed well.
  • Step S204 The drug in the formulated solution is loaded into the micropores of the coating on the surface of the stent body.
  • the stent body having the microporous coating on the surface obtained in the step S202 is immersed in the prepared solution so that the drug in the solution can be loaded in the micropores of the surface of the stent body.
  • Step S205 drying the stent body to obtain an interventional medical device.
  • FIG. 6 is still another process flow of the method for preparing an interventional medical device provided by the present application.
  • the method for preparing the interventional medical device includes: Step S301: Cleaning the stent body and drying.
  • Step S302 A drug for inhibiting proliferation of outer membrane fibroblasts and a mixed solution of a drug and a high molecular polymer which inhibit proliferation of endometrial and/or smooth muscle cells are prepared.
  • the high molecular polymer is selected to be polylactic acid
  • the drug for inhibiting the proliferation of the outer membrane fibroblast is preferably asiaticoside
  • the drug for inhibiting the proliferation of the inner membrane and/or smooth muscle cells is preferably rapamycin.
  • a mixed solution of polylactic acid, asiaticoside and rapamycin is prepared, wherein: the ratio of asiaticoside to rapamycin is 2:1 ⁇ 5: 1, and the ratio of polylactic acid to asiaticoside is 1 : 1 to 5 : 1.
  • 1 Omg of rapamycin and 30 mg of asiaticoside and 100 mg of polylactic acid may be added to 1 Oml of tetrahydrofuran, fully dissolved, and uniformly mixed.
  • Step S303 The mixed solution is coated on the surface of the stent body.
  • the steps may be performed by ultrasonic spraying, air spraying or dip coating.
  • the mixed solution prepared in 302 was applied to the stent body.
  • Step S304 drying the stent body to obtain an interventional medical device.
  • a mixed solution of two drugs with a high molecular polymer is prepared.
  • the two drugs can be separately mixed with the high molecular polymer, and then the mixed solution of the two drugs is sequentially used. They are respectively coated on the surface of the stent body.
  • FIG. 7 is still another process flow of the method for preparing an interventional medical device provided by the present application.
  • the method for preparing the interventional medical device includes: Step S401: Cleaning the stent body and drying.
  • Step S402 separately preparing a mixed solution of a drug and a high molecular polymer for inhibiting proliferation of outer membrane fibroblasts, and a mixed solution of a drug and a high molecular polymer for inhibiting proliferation of endometrial and/or smooth muscle cells.
  • the high molecular polymer is selected as polylactic acid
  • the drug for inhibiting the proliferation of the outer membrane fibroblast is asiaticoside
  • the drug for inhibiting the proliferation of the intima and/or smooth muscle cells is rapamycin.
  • Step S403 The two mixed solutions obtained are sequentially coated on the surface of the stent body.
  • the asiaticoside/polylactic acid solution may be first applied to the surface of the stent body; then the sprayed stent body is placed open for 4 hours to make the surface dry; then rapamycin/poly A lactic acid solution is applied to the surface of the dried stent body.
  • Step S404 drying the stent body to obtain an interventional medical device.

Abstract

L'invention concerne un dispositif médical d'intervention et son procédé de fabrication. Le dispositif médical d'intervention comprend : un corps de support (1), une surface du corps de support (1) comportant une structure de libération de médicament (3), et un médicament dans la structure de libération de médicament (3) qui est un médicament pour supprimer la prolifération de fibroblastes adventitiels et un médicament pour supprimer la prolifération de cellules musculaires de l'intima et/ou lisses. Lors de l'utilisation, après que le dispositif médical d'intervention est implanté dans un corps humain, le médicament pour supprimer la prolifération de fibroblastes adventitiels portés sur celui-ci peut favoriser l'expansion compensatoire du vaisseau, et le médicament pour supprimer la prolifération de cellules musculaires de l'intima et/ou lisses portées pour celui-ci peut supprimer la prolifération de l'intima du vaisseau. La combinaison des deux types de médicament réduit considérablement le taux de survenue de resténose dans une endoprothèse.
PCT/CN2012/070400 2011-09-29 2012-01-16 Dispositif médical d'intervention et son procédé de fabrication WO2013044603A1 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP12834752.3A EP2762110A4 (fr) 2011-09-29 2012-01-16 Dispositif médical d'intervention et son procédé de fabrication
IN2578CHN2014 IN2014CN02578A (fr) 2011-09-29 2012-01-16
US14/348,857 US20140248327A1 (en) 2011-09-29 2012-01-16 Interventional medical device and manufacturing method thereof
BR112014007580A BR112014007580A2 (pt) 2011-09-29 2012-01-16 dispositivo médico de intervenção e método de fabricação do mesmo
US14/677,741 US9433709B2 (en) 2011-09-29 2015-04-02 Interventional medical device and manufacturing method thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201110295324.9 2011-09-29
CN2011102953249A CN102499798A (zh) 2011-09-29 2011-09-29 一种介入医疗器械及其制备方法

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US14/348,857 A-371-Of-International US20140248327A1 (en) 2011-09-29 2012-01-16 Interventional medical device and manufacturing method thereof
US14/677,741 Continuation US9433709B2 (en) 2011-09-29 2015-04-02 Interventional medical device and manufacturing method thereof

Publications (1)

Publication Number Publication Date
WO2013044603A1 true WO2013044603A1 (fr) 2013-04-04

Family

ID=46211977

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2012/070400 WO2013044603A1 (fr) 2011-09-29 2012-01-16 Dispositif médical d'intervention et son procédé de fabrication

Country Status (7)

Country Link
US (2) US20140248327A1 (fr)
EP (1) EP2762110A4 (fr)
JP (1) JP2014530058A (fr)
CN (1) CN102499798A (fr)
BR (1) BR112014007580A2 (fr)
IN (1) IN2014CN02578A (fr)
WO (1) WO2013044603A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20170066450A (ko) * 2014-10-06 2017-06-14 가트 테크놀로지스 비.브이. 조직-접착 다공성 지혈 제품

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102397119A (zh) * 2011-09-29 2012-04-04 微创医疗器械(上海)有限公司 一种介入医疗器械及其制备方法
CN106999284A (zh) * 2014-12-25 2017-08-01 奥林巴斯株式会社 骨接合用植入物及其制造方法
CN105816921A (zh) * 2016-04-20 2016-08-03 山东百多安医用材料改性工程技术中心 一种仿生血管支架及其制备方法
CN106512188A (zh) * 2016-12-13 2017-03-22 天津飞捷科技有限公司 机电一体化靶向药物释放介入类医疗器械及其制备方法
CN109602523B (zh) * 2019-01-03 2024-02-09 科塞尔医疗科技（苏州）有限公司 一种可回收的药物支架
CN110283296B (zh) * 2019-06-20 2020-07-31 中国科学院长春应用化学研究所 双功能聚氨酯及其制备方法与应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1935274A (zh) * 2006-10-20 2007-03-28 东南大学 冠状动脉药物涂层支架
EP2014308A2 (fr) * 2007-07-10 2009-01-14 Cordis Corporation Revêtement utilisant un conjugué anti-thrombotique
CN101879102A (zh) * 2009-05-07 2010-11-10 微创医疗器械(上海)有限公司 一种凹槽携载式涂层可降解型药物洗脱支架

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6273913B1 (en) * 1997-04-18 2001-08-14 Cordis Corporation Modified stent useful for delivery of drugs along stent strut
US6908624B2 (en) * 1999-12-23 2005-06-21 Advanced Cardiovascular Systems, Inc. Coating for implantable devices and a method of forming the same
DK1435877T3 (da) * 2001-10-15 2009-08-03 Hemoteq Ag Overtrækning af stents for at forhindre restenose
EP1308179A1 (fr) * 2001-10-30 2003-05-07 Boehringer Ingelheim Pharma GmbH & Co.KG Dispositif endoprothétique amélioré
US20050019404A1 (en) * 2003-06-30 2005-01-27 Hsing-Wen Sung Drug-eluting biodegradable stent
JP4588986B2 (ja) * 2002-08-20 2010-12-01 テルモ株式会社 体内埋込医療器具
NZ542059A (en) 2003-02-28 2009-11-27 Florey Howard Inst Therapeutic compositions comprising an aryl sulphonate such as suramin, for the treatment of a pathological condition or event of the systemic vasculature resulting form the producation of reactive oxygen species.
US7488343B2 (en) * 2003-09-16 2009-02-10 Boston Scientific Scimed, Inc. Medical devices
US20070219613A1 (en) 2003-10-06 2007-09-20 Xtent, Inc. Apparatus and methods for interlocking stent segments
US8003122B2 (en) 2004-03-31 2011-08-23 Cordis Corporation Device for local and/or regional delivery employing liquid formulations of therapeutic agents
US20050266040A1 (en) * 2004-05-28 2005-12-01 Brent Gerberding Medical devices composed of porous metallic materials for delivering biologically active materials
AU2004322702B2 (en) * 2004-08-13 2011-08-25 Rutgers, The State University Radiopaque polymeric stents
US20060199876A1 (en) * 2005-03-04 2006-09-07 The University Of British Columbia Bioceramic composite coatings and process for making same
US20070224235A1 (en) * 2006-03-24 2007-09-27 Barron Tenney Medical devices having nanoporous coatings for controlled therapeutic agent delivery
US8187620B2 (en) * 2006-03-27 2012-05-29 Boston Scientific Scimed, Inc. Medical devices comprising a porous metal oxide or metal material and a polymer coating for delivering therapeutic agents
US20070292470A1 (en) * 2006-06-15 2007-12-20 Medtronic Vascular, Inc. Implantable Medical Devices and Methods for Making the Same
CA2775940A1 (fr) * 2006-07-03 2008-01-10 Hemoteq Ag Catheter a ballonnet avec revetement polymere
CN101199873B (zh) * 2006-12-14 2013-06-19 乐普（北京）医疗器械股份有限公司 药物洗脱器械用纳米级孔洞药物释放结构及其制备方法
US8187255B2 (en) * 2007-02-02 2012-05-29 Boston Scientific Scimed, Inc. Medical devices having nanoporous coatings for controlled therapeutic agent delivery
JP5461202B2 (ja) * 2007-03-09 2014-04-02 アイコン メディカル コーポレーション 医療用具用生体吸収性コーティング
CN101318032B (zh) 2007-06-06 2012-11-21 李京倖 小口径组织工程学人工血管及其制备方法
CN101406713B (zh) * 2007-10-12 2012-09-19 微创医疗器械(上海)有限公司 一种人工血管支架及其制备方法
CN101945621B (zh) * 2007-12-18 2014-06-18 因特尔赛克特耳鼻喉公司 自扩展装置及用于其的方法
KR100947094B1 (ko) * 2008-01-02 2010-03-10 주식회사 디오 의료용 스텐트 및 그 제조방법
WO2010032643A1 (fr) 2008-09-17 2010-03-25 テルモ株式会社 Endoprothèse
US20100280600A1 (en) * 2009-04-30 2010-11-04 Vipul Bhupendra Dave Dual drug stent
CN102397119A (zh) 2011-09-29 2012-04-04 微创医疗器械(上海)有限公司 一种介入医疗器械及其制备方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1935274A (zh) * 2006-10-20 2007-03-28 东南大学 冠状动脉药物涂层支架
EP2014308A2 (fr) * 2007-07-10 2009-01-14 Cordis Corporation Revêtement utilisant un conjugué anti-thrombotique
CN101879102A (zh) * 2009-05-07 2010-11-10 微创医疗器械(上海)有限公司 一种凹槽携载式涂层可降解型药物洗脱支架

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP2762110A4 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20170066450A (ko) * 2014-10-06 2017-06-14 가트 테크놀로지스 비.브이. 조직-접착 다공성 지혈 제품
JP2017531488A (ja) * 2014-10-06 2017-10-26 ガット テクノロジーズ ビー．ブイ．Ｇａｔｔ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｂ．Ｖ． 組織接着性多孔質止血製品
KR102514142B1 (ko) 2014-10-06 2023-03-27 가트 테크놀로지스 비.브이. 조직-접착 다공성 지혈 제품

Also Published As

Publication number Publication date
JP2014530058A (ja) 2014-11-17
EP2762110A1 (fr) 2014-08-06
US9433709B2 (en) 2016-09-06
BR112014007580A2 (pt) 2017-04-11
CN102499798A (zh) 2012-06-20
IN2014CN02578A (fr) 2015-08-07
US20150209485A1 (en) 2015-07-30
US20140248327A1 (en) 2014-09-04
EP2762110A4 (fr) 2015-05-06

Similar Documents

Publication Publication Date Title
WO2013044605A1 (fr) Dispositif médical interventionnel et procédé de fabrication de celui-ci
WO2013044603A1 (fr) Dispositif médical d'intervention et son procédé de fabrication
JP5368991B2 (ja) 薬剤徐放性ステント
Nazneen et al. Surface chemical and physical modification in stent technology for the treatment of coronary artery disease
WO2008071047A1 (fr) Structure de libération de medicament nanoporeuse pour instruments d'élution de médicaments et son procédé de préparation
CN101327343B (zh) 一种复合药物血管支架及其制备方法
WO2010081393A1 (fr) Appareil d'élution de médicaments avec structure à microtrous capable de stocker et de libérer de multiples médicaments et son procédé d'élaboration
JP2009540931A (ja) ステントコーティングを改変するための凍結−融解法
CN101869723A (zh) 抑制心血管再狭窄的复合药物支架及制备方法
CN107913119A (zh) 一种介入医疗器械及其制备方法
WO2008061431A1 (fr) Stent à plusieurs couches de médicaments
CN101081316A (zh) 一种新型药物洗脱支架
CN101195048A (zh) 一种复合药物洗脱支架及其制备方法
Li et al. In vitro release study of sirolimus from a PDLLA matrix on a bioresorbable drug-eluting stent
US8591571B2 (en) Drug-eluting stent
KR101595267B1 (ko) 재협착과 염증 조절을 위한 순차적 약물 방출 스텐트의 제조방법
JP5422999B2 (ja) コーティング層を有するインプラント
WO2019029334A1 (fr) Médicament composite anti-resténose pour stent coronaire à élution de médicament et système de libération contrôlée correspondant
Gao et al. A new rapamycin-abluminally coated chitosan/heparin stent system accelerates early re-endothelialisation and improves anti-coagulant properties in porcine coronary artery models
JP2016163619A (ja) 防食効果を利用したマグネシウムの分解速度制御
JP2002085549A (ja) 血管内治療用材料および血管内治療用器具
JP2015226574A (ja) 薬剤放出層を有するステント
JP2015154921A (ja) 薬剤徐放性ステント
JP2016005533A (ja) ステント
EP4103245A1 (fr) Administration d'inhibiteurs calcique trpc6 à l'aide de ballonnets, d'endoprothèses ou d'autres dispositifs médicaux

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12834752

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2014532219

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 14348857

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2012834752

Country of ref document: EP

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112014007580

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112014007580

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20140328